Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007
Purpose To assess changes in Medicare payments for neovascular age-related macular degeneration (AMD) since introduction of anti–vascular endothelial growth factor (VEGF) therapies. Design Retrospective, longitudinal cohort study. Methods Using the…